Kaplan Medical Center, Dept of Surgery and Breast Health Center, Rehovot, Israel; Hadassah Hebrew University Medical School, Jerusalem, Israel.
Tel Aviv Sourasky Medical Center, Dept of Surgery, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Eur J Surg Oncol. 2020 Jun;46(6):1041-1045. doi: 10.1016/j.ejso.2019.11.501. Epub 2019 Nov 16.
Breast cancer patients with lymph node (LN) metastases at diagnosis often undergo neoadjuvant therapy (NAT). Identification of a LN which regressed after NAT remains a challenge.
To evaluate marking of involved nodes by tattooing with carbon suspension, and identifying these nodes during surgery.
A small amount (0.2-0.5 ml) of carbon suspension was injected into one or two axillary LNs under ultrasound guidance at the time of LN biopsy or before or shortly after starting NAT for LN positive breast cancer. During surgery an attempt was made to identify and remove the tattooed LN as a separate specimen. All patients underwent sentinel LN mapping and biopsy and/or axillary LN dissection as mandated by their clinical status.
Sixty three patients underwent tattooing of axillary LNs with no complications or adverse events. At surgery a tattooed node was identified in 60 patients (95%; 95% CI 87, 98). Of 56 patients who underwent sentinel mapping with Tc99, in 51 (91%; 95% CI 81, 96) at least one radioactive LN was identified. Of 50 patients in whom both radioactivity and tattoo were identified in axillary LNs, in 40 (80%; 95% CI 67, 89) LNs were radioactive and tattooed, however in 10 patients (20%; 95% CI 11, 33), the tattooed LN was not radioactive.
Tattooing of axillary LNs is safe and easily performed. Tattooing was helpful in identifying the marked LN in the majority of cases. This technique helps to ensure that metastatic LNs are identified and removed at surgery after NAT.
诊断时存在淋巴结(LN)转移的乳腺癌患者常接受新辅助治疗(NAT)。识别经 NAT 后消退的 LN 仍然具有挑战性。
评估使用碳混悬液对受累淋巴结进行标记,并在手术中识别这些淋巴结。
在 LN 活检时或在开始 LN 阳性乳腺癌的 NAT 之前或之后不久,在超声引导下将少量(0.2-0.5 毫升)碳混悬液注入一个或两个腋窝 LN 中。在手术中,尝试识别并切除作为单独标本的标记 LN。所有患者均根据其临床状况接受了前哨淋巴结绘图和活检和/或腋窝淋巴结清扫。
63 例患者行腋窝 LN 碳混悬液标记,无并发症或不良事件。在手术中,在 60 例患者(95%;95%CI 87,98)中识别到标记的 LN。在 56 例接受 Tc99 前哨淋巴结绘图的患者中,在 51 例(91%;95%CI 81,96)中至少识别到一个放射性 LN。在 50 例同时在腋窝 LN 中识别到放射性和标记的患者中,在 40 例(80%;95%CI 67,89)LN 中放射性和标记,然而在 10 例(20%;95%CI 11,33)中,标记的 LN 没有放射性。
腋窝 LN 标记是安全且易于进行的。在大多数情况下,标记对识别标记的 LN 很有帮助。该技术有助于确保在 NAT 后手术中识别和切除转移性 LN。